Wednesday, February 19, 2025
Alcon's Voyager DSLT Device Now Available in the US
Alcon’s automated laser enables treatment without a gonio lens or manual aiming.
2025 News Archive
Tuesday, February 18, 2025
Opus Genetics Announces Update on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the phase 1/2 trial of OPGx-LCA5, with initial data anticipated by Q3 2025. Twelve-month data on the adult cohort to be released in the second quarter of the year.
Tuesday, February 18, 2025
Prevent Blindness Declares Second Annual Retinopathy of Prematurity Awareness Week
The initiative, taking place Feb. 24 to March 2, supports the comprehensive “Prevent Blindness ROP Education and Support Program,” designed to provide education and support for families of children with ROP, promote the role of early intervention programs for these children and explain how allied healthcare professionals assist in continuity of care.
Tuesday, February 18, 2025
Opthea Completes COAST Final Week 52 Patient Visit for Wet AMD
Opthea Limited completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD.
Tuesday, February 18, 2025
New World Medical Receives 510(k) Clearance for VIA360 Surgical System
The VIA360 Surgical System delivers controlled amounts of viscoelastic fluid during ophthalmic surgeries, and is also indicated to cut trabecular meshwork tissue during trabeculotomy procedures.
Monday, February 17, 2025
Optos Introduces New Ultrawidefield Imaging System
The next-generation MonacoPro system integrates ultrawidefield imaging with improved diagnostic support.
Friday, February 14, 2025
Additional Ophthalmic Complications Associated With GLP-1 Use Identified in Case Series
American Academy of Ophthalmology provides guidance in response.
By Sarah Fackler
Friday, February 14, 2025
Glenmark Pharmaceuticals Launches Latanoprost Ophthalmic Solution, 0.005%
Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL) is a bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005% of Upjohn US 2 LLC, the company said in a press release.
Thursday, February 13, 2025
FDA Approves Expanded Label for Astellas Pharma's Izervay
The update removes limitations on treatment duration for GA secondary to AMD.
Thursday, February 13, 2025
Lumevoq Gene Therapy for LHON Shows Sustained Vision Gains
Five-year data from the REFLECT trial of Lumevoq demonstrate long-term efficacy and safety.
Tuesday, February 11, 2025
TECLens Secures $9.3 Million Series A Funding to Advance Its Non-invasive Refractive Technology
The funding is allocated to support the clinical development of the company’s non-incisional refractive correction procedure that leverages corneal cross-linking to reshape the cornea.
Tuesday, February 11, 2025
Virtual Vision Health Unveils Visual Acuity Testing for VR Device
Virtual Vision Health launched Visual Acuity testing on the Virtual Eye VR platform. The company said this addition is part of its commitment to expanding access to advanced eye care and equipping providers with a comprehensive, portable, and cloud-based diagnostic solution.
Tuesday, February 11, 2025
Applied Design, Braille Institute Partner to Launch Typeface for Making Reading Easier
Applied Design, a branding and design company, joined forces with the Braille Institute to launch Atkinson Hyperlegible Next, an enhanced and expanded version of the Atkinson Hyperlegible typeface.
Tuesday, February 11, 2025
Lumenis Launches OptiLIFT Device to Address Lower Lid Laxity, Impaired Blinking
OptiLIFT, a proprietary Dynamic Muscle Stimulation technology for toning facial muscles to address lower lid laxity and impaired blinking without the need for surgery, is now available in the United States. The company expects other markets to follow.
Tuesday, February 11, 2025
4DMT Presents Positive 52-Week Results From Phase 2b Cohort of PRISM Wet AMD Study
3E10 vg/eye achieved an 83% reduction in injection burden vs projected on-label aflibercept 2 mg Q8W, 70% required 0-1 supplemental injection and 57% were injection-free through 52 weeks.
Monday, February 10, 2025
Positive Phase 3 Results for Eyelea HD Injection 8 mg in Patients with Macular Edema Following Retinal Vein Occlusion
Results from the Phase 3 QUASAR were presented at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) 2025 annual meeting and will support the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) in the first quarter of 2025.
Monday, February 10, 2025
DigitalOptometrics to Preview Autonomous Slitlamp With Remote Control Capabilities at Vision Expo East 2025
The autonomous slitlamp allows a staff member or remote doctor to capture images and video with the touch of a button, replicating traditional complete anterior segment evaluations while enabling reliable, repeatable results without requiring specialized training, the company said.
Thursday, February 6, 2025
Prevent Blindness Declares February as AMD and Low Vision Awareness Month
Prevent Blindness provides a wealth of free educational resources on AMD, and materials on low vision, and low vision services.
Thursday, February 6, 2025
Foundation Fighting Blindness to Host Free Webinar on Emerging Gene Therapies for IRDs
The free online course will review several topics, including: Viral delivery systems, surgical techniques, current clinical trials and endpoints, inflammation management, and future directions.
Thursday, February 6, 2025
Qlaris Bio Reports Positive Phase 2 Results for QLS-111 in Glaucoma, OHT Patients
The drug met all primary and secondary endpoints, demonstrating significant intraocular pressure (IOP) reductions and a favorable safety profile.
Thursday, February 6, 2025
EyePoint Reports Positive Results From VERONA Trial for DME
Both Duravyu doses met the primary endpoint of extended time to first supplemental injection vs the aflibercept control, with the 2.7 mg dose delaying the need for additional treatment in 73% of patients.
Wednesday, February 5, 2025
Eyenovia Makes Progress on its Next-Generation Optejet Dispensing Device
The company plans to file for US regulatory approval for its novel, user-filled spray dispenser in the fourth quarter of this year.
Tuesday, February 4, 2025
FDA Approves Genentech’s Susvimo for the Treatment of DME
Genentech’s Susvimo (ranibizumab injection) 100 mg/mL is the first continuous-delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME), the company said.
Tuesday, February 4, 2025
FDA Clears EssilorLuxottica's Nuance Audio Smart Glasses
The device, which integrates hearing aid functionality into a pair of smart glasses, is designed to offer both vision and hearing support in a single product.
Monday, February 3, 2025
New Test Detects Parent-of-Origin in Retinoblastoma
Origin matters for this hereditary ocular cancer because researchers found that male and female copies of the mutation are associated with different disease trajectories, and so would likely influence physicians' treatment recommendations.
Monday, February 3, 2025
Rayner Completes US Recruitment for RayOne Galaxy IOL IDE
Rayner has now closed recruitment in the Investigational Device Exemption study for the RayOne Galaxy intraocular lens in the United States.
Monday, February 3, 2025
BVI Medical Launches Educational Platform for Ophthalmic Surgeons
EyeXchange Solutions connects experienced and emerging surgeons across cataract, glaucoma, and retina specialties to share insights, refine techniques, and address complex cases.
Thursday, January 30, 2025
PulseSight Therapeutics Announces Initiation of Clinical Plan of Transferrin Vectorized Therapy for Dry AMD, GA
PulseSight Therapeutics submitted a Clinical Trial Authorization to France's regulatory agency for PST-611, a first-in-class non-viral vectorized therapy for the treatment of dry age-related macular degeneration and geographic atrophy.
Thursday, January 30, 2025
Ocular Therapeutix Shares SOL-R Enrollment Progress, Next Steps for Axpaxli in NPDR
Ocular Therapeutix outlined the clinical progress across its registrational program for Axpaxli in wet age-related macular degeneration (wet AMD), plans to advance Axpaxli in non-proliferative diabetic retinopathy (NPDR), and the company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).
Thursday, January 30, 2025
Harrow Partners With Cencora to Launch Harrow Cares Program
According to Harrow, Harrow Cares ensures seamless enrollment, rapid access to therapy, and personalized support, enabling retina providers to confidently utilize Iheezo and Triesence in their practices.
Wednesday, January 29, 2025
OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Q2
The Phase 2a study is designed as a double-masked, randomized, 12-week placebo-controlled trial in neuropathic corneal pain patients. A total of 48 patients are planned to be enrolled in the trial, with NCP disease confirmed via confocal microscopy, patient symptoms and medical histories.
Tuesday, January 28, 2025
AI Optics Receives FDA 510(k) Clearance for Handheld Retinal Imaging System
AI Optics' Sentinel Camera is a handheld retinal imaging system that captures high-quality images of the human eye.
Tuesday, January 28, 2025
Prevent Blindness Receives Largest Donation in Organization's 117-year History
Prevent Blindness received a $9.7 million donation from the Estate of Pamela Behrens, a long-time Florida resident and previous donor. The largest in Prevent Blindness's history, the donation will help support its mission to prevent blindness and preserve sight across the United States and its commitment to be a partner to organizations working to address eye health around the world.
Monday, January 27, 2025
Norlase Receives 510(k) Clearance, CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscope
Norlase says the battery-powered device is “the world's first and only pattern scanning laser indirect ophthalmoscope.”
Friday, January 24, 2025
Outlook Therapeutics Presents Efficacy, Safety Results from Clinical Trial Evaluating ONS-5010 for Wet AMD at Hawaiian Eye and Retina
Results confirmed that intravitreal ONS-5010 provided early and sustained anatomic improvements, with steady gains in BCVA and reliable, consistent safety, the company said.
Friday, January 24, 2025
AMA Comments on Recent Statement by US Insurer UnitedHealth
The American Medical Association comments on a recent statement by US insurer UnitedHealth that it will work toward easing prior authorization rules.
Friday, January 24, 2025
Heidelberg Symposium to Highlight Glaucoma Innovations
The event, held at Mainz University Medical Center in Mainz, Germany, will showcase the growing role of artificial intelligence in glaucoma diagnosis and management.
Wednesday, January 22, 2025
OKYO Pharma Receives $1.4 Million in Non-Dilutive Funding for NCP and DED
The funding will be strategically allocated to support ongoing research and development initiatives, with particular emphasis on OKYO’s lead program, OK-101, focused on treating neuropathic corneal pain.
Wednesday, January 22, 2025
MeiraGTx Receives Rare Pediatric Disease Designation from US FDA
The designation is for the company's AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). It makes the fourth Rare Pediatric Disease Designation MeiraGTx has received for inherited retinal diseases.
Tuesday, January 21, 2025
Nacuity Pharmaceuticals Granted FDA Fast Track Designation for Retinitis Pigmentosa Therapy
Fast Track Designation represents an objective assessment by the FDA for the potential of NPI-001 tablets as a treatment for retinitis pigmentosa, the company said.
Tuesday, January 21, 2025
Study Shows Association Between Traffic-related Air Pollution, Risk of Outpatient Visits for DED
Short-term exposure to traffic-related air pollutants were linked with a risk of dry eye disease outpatient visits.
Tuesday, January 21, 2025
iCare to Launch New Version of the iCare MAIA Microperimeter
The new iCare MAIA features a renewed hardware platform with fully automated operations and a 15’’ multi-touch display, along with an intuitive user interface.
Thursday, January 16, 2025
Character Biosciences, Bausch + Lomb Collaborate to Develop Treatments for Patients with AMD
The partnership will initially focus on AMD, with the potential to expand into other eye conditions.
Thursday, January 16, 2025
Los Angeles County Wildfires Prompt SBA to Open Local Business Recovery Centers
Attention private practice owners: The U.S. Small Business Administration (SBA) has opened two Business Recovery Centers (BRC) in Los Angeles County to help.
Wednesday, January 15, 2025
GenSight Biologics Publishes 5-Year Outcomes for Patients Treated Unilaterally with LUMEVOQ
Five years after the one-time injection, patients with Leber hereditary optic neuropathy due to the MT-ND4 gene variant demonstrated sustained bilateral improvement in visual acuity and a favorable safety profile.
Wednesday, January 15, 2025
Inflammasome Therapeutics Reports Topline 3-month Data from a Clinical Trial of First-in-Class Dual Inflammasome Inhibitor in GA
In a US clinical trial of five patients with bilateral geographic atrophy, sustained-release intravitreous implants of K8 were well tolerated, with no drug-related ocular or systemic serious adverse events.
Wednesday, January 15, 2025
Sling Therapeutics Announces Positive Topline Results from Phase 2b/3 LIDS Clinical Trial of Oral Small Molecule Linsitinib in Patients with TED
The LIDS trial met its primary endpoint with statistical significance for the 150 mg BID dose.
Tuesday, January 14, 2025
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Trial in DME
The 3E10 vg/eye dose demonstrated notable efficacy, achieving sustained visual acuity gains.
By Jennifer Ford, content director
Tuesday, January 14, 2025
HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC, UIC
These collaborations establish two new simulation-based surgical training locations to advance ophthalmic education while also addressing the global cataract blindness crisis.
Tuesday, January 14, 2025
Bausch + Lomb, GRF Launch Second Annual ‘Faces of Glaucoma’ Campaign and Fundraising Challenge
Throughout January, Bausch + Lomb and Glaucoma Research Foundation will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness of the disease.
Tuesday, January 14, 2025
City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-based Treatment for GA
Through the collaboration, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.
Tuesday, January 14, 2025
Alkeus Reports Positive Interim Results Showing Gildeuretinol Prevented Disease Progression in Early-Stage Stargardt Patients
The data demonstrated that additional early-stage Stargardt disease patients treated with oral gildeuretinol acetate showed no disease progression, including stable visual acuity, over multiple years.
Tuesday, January 14, 2025
Samsara Reports Positive 6-Month Visual and Safety Outcomes from the SING IMT
The study showed that the percentage of patients able to read at near distance increased from 28.6% at baseline to 97.1% at 6 months.
Monday, January 13, 2025
Bausch + Lomb Acquires Whitecap Biosciences
With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Biosciences strengthens B + L’s expanding clinical-stage pipeline.
Monday, January 13, 2025
Zeiss's MEL 90 Excimer Laser Wins FDA Approval
The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE and completes Corneal Refractive Workflow, company says.
Friday, January 10, 2025
Tenpoint Reports Positive Data from BRIO-II Phase 3 Pivotal Study of BRIMOCHOL PF for Presbyopia
Tenpoint Therapeutics' BRIMOCHOL PF successfully met the pre-specified visual acuity primary endpoints for both the United States and EU/UK with highly statistically significant near- vision improvements over 8 hours.
Thursday, January 9, 2025
FDA Clears Epithelial Thickness Module for Heidelberg Engineering’s Anterion Multidisciplinary Imaging Platform
The module equips eye-care professionals with advanced thickness mapping and data insights to evaluate both the epithelial and stromal structures.
Thursday, January 9, 2025
FDA Confirms Class 1 Resubmission of the Supplemental NDA for IZERVAY for Geographic Atrophy
The supplemental new drug application seeks to add positive 2-year data to the IZERVAY U.S. Prescribing Information based on results from the GATHER2 Phase 3 clinical trial.
Thursday, January 9, 2025
Rayner Launches Redesigned Online Premium IOL Calculator, Raytrace
The newly-redesigned RayTrace version 4.0 reflects surgeon feedback with quicker and clearer calculations, access to the PEARL DGS formula, and a host of other new features.
Wednesday, January 8, 2025
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients
The research team demonstrated the effectiveness of their technique in multiple models, including human tissues.
Tuesday, January 7, 2025
Sozinibercept Shows Efficacy as Diabetic Macular Edema Treatment
Recently published results of a Phase 1 study support its potential in combination with aflibercept.
Tuesday, January 7, 2025
Canyon Labs to Acquire iuvo BioScience's Labs Services and Consulting Business
The strategic acquisition enables Canyon to expand its end-to-end development solutions and strengthens both organizations' market positions.
Tuesday, January 7, 2025
Regeneron Acquires Biotech Firm Oxular
The acquisition will strengthen Regeneron Pharmaceuticals' gene therapy development program.
Tuesday, January 7, 2025
Cencora Finalizes Retina Consultants of America Acquisition
The acquisition aims to strengthen Cencora’s position in the specialty health-care market and expand its management services organization offerings.
Tuesday, January 7, 2025
Soliddd Introduces Smartglasses Technology at CES 2025
SolidddVision’s vision correction technology can improve sight for patients with macular degeneration and other conditions.
Tuesday, January 7, 2025
EssilorLuxottica Announces Agreement to Acquire Espansione Group
EssilorLuxottica aims to leverage Espansione’s technology to advance its mission of improving vision health.
Tuesday, January 7, 2025
Galimedix Initiates Trial for Dry AMD Eyedrops
The Phase 2 study will examine GAL-101’s potential to slow the growth of geographic atrophy lesions.
Monday, January 6, 2025
Oculis Phase 2 ACUITY Trial in Acute Optic Neuritis Meets Primary Safety Endpoint, Key Secondary Efficacy Endpoints
Oculis' OCS-05 showed a favorable safety and tolerability profile compared to placebo, and achieved statistically significant results on key secondary efficacy endpoints compared to placebo, including objective structural measures of retinal thickness and visual improvement.
Friday, January 3, 2025
Prevent Blindness Offers Free Resources for National Glaucoma Awareness Month
In an effort to support National Glaucoma Awareness Month in January, Prevent Blindness is providing patients, care partners and professionals with free educational resources.
Thursday, January 2, 2025
Valo Health Suspends Development of Diabetic Retinopathy Drug
While the Phase 2 SPECTRA study did not meet its primary or secondary endpoints based on the analysis in the predefined primary population, certain doses tested in the study showed potential evidence of preventing disease progression.
Thursday, January 2, 2025
Mandatory Patient Experience Evaluating Reporting (OHS CAHPS) Begins Now
New year, new requirements: OOSS warns ACS that do not administer and report OHS CAHPS in 2025 could be subject to a penalty of 2% of their annual Medicare payment update.
Advertisement
Recommendations
Advertisement